A potential novel biomarker of multiple sclerosis subtype and prognosis

Takeaway

  • The transforming growth factor-α (TGF-α)/vascular endothelial growth factor B (VEGF-B) ratio was altered depending on multiple sclerosis (MS) subtype, severity, and disease activity.

Why this matters

  • The aryl hydrocarbon receptor (AHR)-dependent TGF-α/VEGF-B ratio regulates the effects of metabolic, microbial, and dietary factors on acute and chronic CNS inflammation.

  • Changes in the TGF-α/VEGF-B ratio correlated with specific disease stages and prognosis, suggesting that this ratio could be used as a novel marker to monitor and improve therapy in MS.